FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283266447> ?p ?o ?g. }

• W4283266447 abstract "Abstract Evidence is scant regarding the long-term humoral and cellular responses triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in cancer patients after repeated booster doses. The possibility of T-cell exhaustion following these booster doses in this population has not yet been fully studied and remains uncertain. In this observational study, we explored the specific humoral and cellular response to S1 antigen in 36 patients with solid malignancies at baseline, and after the second and third doses of the mRNA-1273 vaccine. A dual behavior was observed: 24 (66.7%) patients showed partial specific IFN-γ response after the second dose that was further enhanced after the third dose; and 11 (30.5%) already showed an optimal response after the second dose and experienced a marked fall-off of specific IFN-γ production after the third (4 patients negativization), which might suggest T cell exhaustion due to repetitive priming to the same antigen. One (2.8%) patient had persistently negative responses after all three doses. Seroconversion occurred in all patients after the second dose. We then studied circulating exhausted CD8 + T-cells in 4 patients from each of the two response patterns, those with increase and those with decrease in cellular response after the third booster. The patients with decreased cellular response after the booster had a higher expression of CD57 hi PD1 hi CD8 + and CD57 int PD1 hi CD8 + exhausted T cells compared with those with an increased cellular response both in vivo and in vitro . Our preliminary data show that the two-dose SARS-CoV-2 vaccine regimen was beneficial in all cancer patients. An additional booster seems to be beneficial in non-optimal cancer responders to SARS-CoV-2 vaccines, in contrast to maximal responders that might develop exhaustion. Our data should be interpreted with caution given the small sample size and highlight the urgent need to validate our results in other independent and larger cohorts. Altogether, our data support the relevance of immunological functional studies to personalize preventive and treatment decisions in cancer patients." @default.
• W4283266447 created "2022-06-23" @default.
• W4283266447 creator A5007294209 @default.
• W4283266447 creator A5015518044 @default.
• W4283266447 creator A5032282735 @default.
• W4283266447 creator A5040372527 @default.
• W4283266447 creator A5040663702 @default.
• W4283266447 creator A5059383103 @default.
• W4283266447 creator A5061030816 @default.
• W4283266447 creator A5065933823 @default.
• W4283266447 creator A5066457036 @default.
• W4283266447 creator A5067993727 @default.
• W4283266447 creator A5068109247 @default.
• W4283266447 creator A5068795574 @default.
• W4283266447 creator A5069385617 @default.
• W4283266447 creator A5072879741 @default.
• W4283266447 creator A5077220786 @default.
• W4283266447 creator A5084038731 @default.
• W4283266447 creator A5084425257 @default.
• W4283266447 date "2022-06-22" @default.
• W4283266447 modified "2023-10-18" @default.
• W4283266447 title "Evidence of Exhausted Lymphocytes after the Third anti-SARS-CoV-2 Vaccine Dose in Cancer Patients" @default.
• W4283266447 doi "https://doi.org/10.21203/rs.3.rs-1777911/v1" @default.
• W4283266447 hasPublicationYear "2022" @default.
• W4283266447 type Work @default.
• W4283266447 citedByCount "0" @default.
• W4283266447 crossrefType "posted-content" @default.
• W4283266447 hasAuthorship W4283266447A5007294209 @default.
• W4283266447 hasAuthorship W4283266447A5015518044 @default.
• W4283266447 hasAuthorship W4283266447A5032282735 @default.
• W4283266447 hasAuthorship W4283266447A5040372527 @default.
• W4283266447 hasAuthorship W4283266447A5040663702 @default.
• W4283266447 hasAuthorship W4283266447A5059383103 @default.
• W4283266447 hasAuthorship W4283266447A5061030816 @default.
• W4283266447 hasAuthorship W4283266447A5065933823 @default.
• W4283266447 hasAuthorship W4283266447A5066457036 @default.
• W4283266447 hasAuthorship W4283266447A5067993727 @default.
• W4283266447 hasAuthorship W4283266447A5068109247 @default.
• W4283266447 hasAuthorship W4283266447A5068795574 @default.
• W4283266447 hasAuthorship W4283266447A5069385617 @default.
• W4283266447 hasAuthorship W4283266447A5072879741 @default.
• W4283266447 hasAuthorship W4283266447A5077220786 @default.
• W4283266447 hasAuthorship W4283266447A5084038731 @default.
• W4283266447 hasAuthorship W4283266447A5084425257 @default.
• W4283266447 hasBestOaLocation W42832664471 @default.
• W4283266447 hasConcept C100701293 @default.
• W4283266447 hasConcept C12590561 @default.
• W4283266447 hasConcept C147483822 @default.
• W4283266447 hasConcept C150903083 @default.
• W4283266447 hasConcept C159654299 @default.
• W4283266447 hasConcept C167672396 @default.
• W4283266447 hasConcept C203014093 @default.
• W4283266447 hasConcept C207001950 @default.
• W4283266447 hasConcept C2777451964 @default.
• W4283266447 hasConcept C2780801004 @default.
• W4283266447 hasConcept C2908647359 @default.
• W4283266447 hasConcept C3017875465 @default.
• W4283266447 hasConcept C59822182 @default.
• W4283266447 hasConcept C71924100 @default.
• W4283266447 hasConcept C81444415 @default.
• W4283266447 hasConcept C86803240 @default.
• W4283266447 hasConcept C8891405 @default.
• W4283266447 hasConcept C99454951 @default.
• W4283266447 hasConceptScore W4283266447C100701293 @default.
• W4283266447 hasConceptScore W4283266447C12590561 @default.
• W4283266447 hasConceptScore W4283266447C147483822 @default.
• W4283266447 hasConceptScore W4283266447C150903083 @default.
• W4283266447 hasConceptScore W4283266447C159654299 @default.
• W4283266447 hasConceptScore W4283266447C167672396 @default.
• W4283266447 hasConceptScore W4283266447C203014093 @default.
• W4283266447 hasConceptScore W4283266447C207001950 @default.
• W4283266447 hasConceptScore W4283266447C2777451964 @default.
• W4283266447 hasConceptScore W4283266447C2780801004 @default.
• W4283266447 hasConceptScore W4283266447C2908647359 @default.
• W4283266447 hasConceptScore W4283266447C3017875465 @default.
• W4283266447 hasConceptScore W4283266447C59822182 @default.
• W4283266447 hasConceptScore W4283266447C71924100 @default.
• W4283266447 hasConceptScore W4283266447C81444415 @default.
• W4283266447 hasConceptScore W4283266447C86803240 @default.
• W4283266447 hasConceptScore W4283266447C8891405 @default.
• W4283266447 hasConceptScore W4283266447C99454951 @default.
• W4283266447 hasFunder F4320325516 @default.
• W4283266447 hasLocation W42832664471 @default.
• W4283266447 hasOpenAccess W4283266447 @default.
• W4283266447 hasPrimaryLocation W42832664471 @default.
• W4283266447 hasRelatedWork W1724539479 @default.
• W4283266447 hasRelatedWork W2001055320 @default.
• W4283266447 hasRelatedWork W2022517847 @default.
• W4283266447 hasRelatedWork W2031356189 @default.
• W4283266447 hasRelatedWork W2061709326 @default.
• W4283266447 hasRelatedWork W2085713490 @default.
• W4283266447 hasRelatedWork W2220102944 @default.
• W4283266447 hasRelatedWork W2404959002 @default.
• W4283266447 hasRelatedWork W4311313023 @default.
• W4283266447 hasRelatedWork W4313292197 @default.
• W4283266447 isParatext "false" @default.
• W4283266447 isRetracted "false" @default.
• W4283266447 workType "article" @default.